Home > News

Follow Us

A cure for type 1 diabetes

Read about the novel clinical study.

Diabetes researcher Denis Faustman, MD, PhD and colleagues at Massachusetts General Hospital (MGH) are using Mercodia´s C-Peptide kits in a novel type 1 diabetes clinical study.

The trial is testing whether using a generic drug to temporarily elevate tumor necrosis factor-alpha (TNF-a) levels in the body will reduce or eliminate autoimmune T cells in patients with established type 1 diabetes, an approach based on the Faustman lab’s previous success in reversing end-stage diabetes in mice. To learn more, please visit www.faustmanlab.org  www.faustmanlab.org

 

Additional Links of Interest

Listen as Dr. Faustman describes her own research in "EFTR: Targeting Diabetes with an Old TB Vaccine"

 

05/05/14 Combining two technologies may increase the effectiveness of oral insulin

04/10/14 Supplemental diets for cows benefit their performance

04/01/14 Mercodia announces collaboration with Chongqing Zhongyuan Biotechnology Co in China

03/20/14 Blocking Ca-ion flow alleviates hypoxia-induced damage to beta cells

03/10/14 NEW – Mercodia Launches Rat Glicentin ELISA

02/27/14 Glucagon WEBINAR with Professor Jens Juul Holst

More news and archive | Return | Print